| Ytd | -27.78% | |
| 1y | 38.17% |
| Open | 14.73 | Prev Close | 14.30 | Low | 13.18 | High | 15.92 | Mkt Cap | 1.11B |
| Vol | 2.15M | Avg Vol | 1.07M | EPS | -3.51 | P/E | N/A | Forward P/E | -4.68 |
| Beta | 1.75 | Short Ratio | 14.51 | Inst. Own | 111.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.17 | 200-d Avg | 14.13 | 1yr Est | 40.00 |
Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near t